Everolimus plus exemestane for hormonereceptor- positive, human epidermal growth factor receptor-2-negative advanced breast cancer: Overall survival results from BOLERO-2

Annals of Oncology

Volumn 25, Issue 12, 2014, Pages 2357-2362

  Piccart, Martine ^a   Hortobagyi, G N ^b   Campone, M ^c   Pritchard, K I ^d   Lebrun, F ^a   Ito, Y ^e   Noguchi, S ^f   Perez, A ^g   Rugo, H S ^h   Deleu, I ⁱ   Burris, H A ^j   Provencher, L ^k   Neven, P ^l   Gnant, M ^m   Shtivelband, M ⁿ   Wu, C ^o   Fan, J ^o   Feng, W ^o   Taran, T ^o   Baselga, J ^p  

^a JULES BORDET INSTITUTE   (Belgium)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Institut de Cancérologie de l'Ouest René Gauducheau   (France)

^d UNIVERSITY OF TORONTO   (Canada)

^e CANCER INSTITUTE HOSPITAL   (Japan)

^f OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g Memorial Cancer Institute   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ AZ Nikolaas   (Belgium)

^j SARAH CANNON RESEARCH INSTITUTE   (United States)

^k LAVAL UNIVERSITY   (Canada)

^l UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^m MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁿ Ironwood Cancer and Research Center   (United States)

^o NOVARTIS PHARMA AG   (Switzerland)

^p MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

Everolimus; Exemestane; Hormone receptor positive breast cancer; Overall survival

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; EXEMESTANE; HORMONE RECEPTOR; PLACEBO; ANDROSTANE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; RAPAMYCIN;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; BREAST TUMOR; CLINICAL TRIAL; METABOLISM; SURVIVAL;

ANDROSTADIENES; BREAST NEOPLASMS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; PLACEBOS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIROLIMUS; SURVIVAL ANALYSIS;

EID: 84921807735     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu456     Document Type: Article

References (40)

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, v2.2014. www.nccn.org (3 April 2014, date last accessed).
2. Cardoso F, Costa A, Norton L et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 2012; 21: 242-252.
3. Chia S, Gradishar W, Mauriac L et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 2008; 26: 1664-1670.
4. Di Leo A, Jerusalem G, Petruzelka L et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010; 28: 4594-4600.
5. Johnston SR, Kilburn LS, Ellis P et al. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol 2013; 14: 989-998.
6. Yardley DA, Noguchi S, Pritchard KI et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progressionfree survival analysis. Adv Ther 2013; 30: 870-884.
7. Rugo HS, Pritchard KI, Gnant M et al. Incidence and time course of everolimusrelated adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Ann Oncol 2014; 25: 808-815.
8. Burris HA, III, Lebrun F, Rugo HS et al. Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. Cancer 2013; 119: 1908-1915.
9. Baselga J, Campone M, Piccart M et al. Everolimus in postmenopausal hormonereceptor-positive advanced breast cancer. N Engl J Med 2012; 366: 520-529.
10. Giuliano M, Schifp R, Osborne CK, Trivedi MV. Biological mechanisms and clinical implications of endocrine resistance in breast cancer. Breast 2011; 20(Suppl 3): S42-S49.
11. Garcia-Becerra R, Santos N, Diaz L, Camacho J. Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance. Int J Mol Sci 2012; 14: 108-145.
12. Jeselsohn R, Yelensky R, Buchwalter G et al. Emergence of constitutively active estrogen receptor-alpha mutations in pretreated advanced estrogen receptorpositive breast cancer. Clin Cancer Res 2014; 20: 1757-1767.
13. Robinson DR, Wu YM, Vats P et al. Activating ESR1 mutations in hormoneresistant metastatic breast cancer. Nat Genet 2013; 45: 1446-1451.
14. Toy W, Shen Y, Won H et al. ESR1 ligand-binding domain mutations in hormoneresistant breast cancer. Nat Genet 2013; 45: 1439-1445.
15. Martinez-Galan J, Torres-Torres B, Nunez MI et al. ESR1 gene promoter region methylation in free circulating DNA and its correlation with estrogen receptor protein expression in tumor tissue in breast cancer patients. BMC Cancer 2014; 14: 59.
16. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009; 9: 631-643.
17. Johnston S, Pippen J, Jr, Pivot X et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptorpositive metastatic breast cancer. J Clin Oncol 2009; 27: 5538-5546.
18. Kaufman B, Mackey JR, Clemens MR et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009; 27: 5529-5537.
19. Mauriac L, Cameron D, Dirix L et al. Results of randomized phase II trial combining Iressa® (gefitinib) and arimidex in women with advanced breast cancer (ABC). EORTC protocol 10021. Cancer Res 2009; 69(2 Suppl 1): abstract 6133.
20. Osborne CK, Neven P, Dirix LY et al. Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res 2011; 17: 1147-1159.
21. Robertson JF, Ferrero JM, Bourgeois H et al. Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial. Lancet Oncol 2013; 14: 228-235.
22. Campbell RA, Bhat-Nakshatri P, Patel NM et al. Phosphatidylinositol 3-kinase/AKTmediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 2001; 276: 9817-9824.
23. Clark AS, West K, Streicher S, Dennis PA. Constitutive and inducible AKT activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 2002; 1: 707-717.
24. Simoncini T, Hafezi-Moghadam A, Brazil DP et al. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 2000; 407: 538-541.
25. Wolff AC, Lazar AA, Bondarenko I et al. Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol 2013; 31: 195-202.
26. Baselga J, Semiglazov V, van Dam P et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009; 27: 2630-2637.
27. Bachelot T, Bourgier C, Cropet C et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 2012; 30: 2718-2724.
28. Chia S, Piccart M, Gradishar W. Fulvestrant versus Exemestane Following non-Steroidal Aromatase Inhibitor Failure: First Overall Survival Data from the EFECT Trial. In San Antonio Breast Cancer Symposium (Poster 2091). San Antonio, TX 2007.
29. Baselga J, Cortes J, Kim SB et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366: 109-119.
30. Wan X, Harkavy B, Shen N et al. Rapamycin induces feedback activation of AKT signaling through an IGF-1R-dependent mechanism. Oncogene 2007; 26: 1932-1940.
31. LoRusso PM. Mammalian target of rapamycin as a rational therapeutic target for breast cancer treatment. Oncology 2013; 84: 43-56.
32. McArthur GA, Chapman PB, Robert C et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014; 15: 323-332.
33. Shaw AT, Kim DW, Nakagawa K et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368: 2385-2394.
34. Mehta RS, Barlow WE, Albain KS et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 2012; 367: 435-444.
35. Kaufmann M, Bajetta E, Dirix LY et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 2000; 18: 1399-1411.
36. Howell A, Robertson JFR, Abram P et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004; 22: 1605-1613.
37. Di Leo A, Jerusalem G, Petruzelka L et al. Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst 2014; 106: djt337.
38. Yardley DA, Ismail-Khan RR, Melichar B et al. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptorpositive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol 2013; 31: 2128-2135.
39. Andre F, Bachelot T, Campone M et al. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin Cancer Res 2013; 19: 3693-3702.
40. Finn RS, Crown JP, Lang I et al. Phase II study of palbociclib (PD-0332991) + letrozole vs letrozole alone in first-line ER+/HER2-advanced breast cancer. Ann Oncol 2013; 24(Suppl 9): ix32-ix33; abstract O31-030.